Related references
Note: Only part of the references are listed.Immune responses in genomically simple SWI/SNF-deficient cancers
Amaury Leruste et al.
CANCER (2021)
Emerging role of SWI/SNF complex deficiency as a target of immune checkpoint blockade in human cancers
Min Zhou et al.
ONCOGENESIS (2021)
The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker
Denis L. Jardim et al.
CANCER CELL (2021)
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
Kevin Litchfield et al.
CELL (2021)
PL01.05 The New WHO Classification of Lung Tumors
M. Tsao
Journal of Thoracic Oncology (2021)
Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma
Hayato Kawachi et al.
IMMUNOTHERAPY (2021)
PD1 inhibition in soft-tissue sarcomas with tertiary lymphoid structures: A multicenter phase II trial.
Antoine Italiano et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma (ASPS) and other rare sarcoma histotypes: The French AcSe pembrolizumab study from Unicancer.
Jean-Yves Blay et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Ipilimumab and Pembrolizumab Mixed Response in a 41-Year-Old Patient with SMARCA4-Deficient Thoracic Sarcoma: An Interdisciplinary Case Study
Nina Anzic et al.
CASE REPORTS IN ONCOLOGY (2021)
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression
Lucile Vanhersecke et al.
NATURE CANCER (2021)
Tumor-infiltrating lymphocytes in the immunotherapy era
Sterre T. Paijens et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
Cytopathological Features of SMARCA4-Deficient Thoracic Sarcoma: Report of 2 Cases and Review of the Literature
Maiko Takeda et al.
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY (2020)
The Cancer Immunotherapy Biomarker Testing Landscape
Eric E. Walk et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2020)
Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab
Emily Z. Keung et al.
CLINICAL CANCER RESEARCH (2020)
B cells are associated with survival and immunotherapy response in sarcoma
Florent Petitprez et al.
NATURE (2020)
Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy
Jing Li et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma
Xian-De Liu et al.
NATURE COMMUNICATIONS (2020)
Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors
Sarah Abou Alaiwi et al.
CANCER IMMUNOLOGY RESEARCH (2020)
The SWI/SNF complex in cancer - biology, biomarkers and therapy
Priya Mittal et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer
Adamj. Schoenfeld et al.
CLINICAL CANCER RESEARCH (2020)
Toward Systems Biomarkers of Response to Immune Checkpoint Blockers
Oscar Lapuente-Santana et al.
FRONTIERS IN ONCOLOGY (2020)
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden
D. Marinelli et al.
ANNALS OF ONCOLOGY (2020)
Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma
Julien Calderaro et al.
JOURNAL OF HEPATOLOGY (2019)
Imaging features of SMARCA4-deficient thoracic sarcomas: a multi-centric study of 21 patients
Amandine Crombe et al.
EUROPEAN RADIOLOGY (2019)
Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor
C. Henon et al.
ANNALS OF ONCOLOGY (2019)
Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients
Michael J. Duffy et al.
CLINICAL CHEMISTRY (2019)
Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma
David A. Braun et al.
JAMA ONCOLOGY (2019)
Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: A case report
Kohichi Takada et al.
THORACIC CANCER (2019)
SMARCA4-deficient Thoracic Sarcomas Clinicopathologic Study of 30 Cases With an Emphasis on Their Nosology and Differential Diagnoses
Raul Perret et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2019)
An In-Depth Look at Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT): Clinical Implications from Recent Molecular Findings
Bingjian Lu et al.
JOURNAL OF CANCER (2019)
Tertiary lymphoid structures in the era of cancer immunotherapy
Catherine Sautes-Fridman et al.
NATURE REVIEWS CANCER (2019)
Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade
Petar Jelinic et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Diana Miao et al.
SCIENCE (2018)
Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade
Petar Jelinic et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Modular Organization and Assembly of SWI/SNF Family Chromatin Remodeling Complexes
Nazar Mashtalir et al.
CELL (2018)
Frameshift events predict anti-PD-1/L1 response in head and neck cancer
Glenn J. Hanna et al.
JCI INSIGHT (2018)
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
Hussein A. Tawbi et al.
LANCET ONCOLOGY (2017)
Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials
Roman Groisberg et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression
Etienne Becht et al.
GENOME BIOLOGY (2016)
SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas
Francois Le Loarer et al.
NATURE GENETICS (2015)
Tertiary lymphoid structures in cancer and beyond
Marie-Caroline Dieu-Nosjean et al.
TRENDS IN IMMUNOLOGY (2014)
STAR: ultrafast universal RNA-seq aligner
Alexander Dobin et al.
BIOINFORMATICS (2013)
Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy
Cigall Kadoch et al.
NATURE GENETICS (2013)
The Spectrum of SWI/SNF Mutations, Ubiquitous in Human Cancers
A. Hunter Shain et al.
PLOS ONE (2013)
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Bo Li et al.
BMC BIOINFORMATICS (2011)
Share Paper
